Overview

A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation

Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
This trial is a multi-center, double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of AXS-05 compared to placebo for the treatment of agitation associated with Alzheimer's disease.
Phase:
Phase 3
Details
Lead Sponsor:
Axsome Therapeutics, Inc.